Home / Healthcare/ Johnson & Johnson says to work on India compensation for recalled hip implants

Johnson & Johnson says to work on India compensation for recalled hip implants


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 12 September 2018 00:00


Mumbai (Reuters): Johnson & Johnson (J&J) said on Friday it would work with the Indian government to compensate patients who suffered from artificial hip implants the US healthcare company recalled eight years ago.

Last month, a government panel recommended that J&J pay compensation of at least INR 2 million ($27,812) to each patient who received an ASR hip implant in India, an estimated 4,700 people. The federal government has asked states to help the patients get relief soon.

“We have always been and continue to be fully committed to supporting all ASR patients in India, and the rest of the world,” a J&J spokeswoman said in a statement emailed to Reuters.

“In light of the recent committee report, we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need,” she added.

The ASR hip implants were recalled in 2010 after data suggested they failed at a higher-than-expected rate.

In 2013, the firm agreed to pay nearly $2.5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants.

In India, the company paid $2 million to patients for repeat surgeries and about $250,000 in related diagnostic costs under its ASR reimbursement program, but the government panel criticised J&J for offering no compensation.

About 93,000 people worldwide received ASR implants, the panel said in its report to the government, about 4,700 of them in India.

Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic, ball-and-socket design. But many Indian patients suffered adverse reactions to the implant, the panel said.

J&J entered the Indian market in 1947 when it started selling its now-ubiquitous baby powder. The company has in recent years faced issues such as price caps on medical devices.

 


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Red flag over the Sri Lankan Navy

Friday, 21 September 2018

Shocking story Rusiripala, a former banker in Sri Lanka, who has taken to writing in Daily FT, is perturbed by the red flag I have raised (Daily FT article 18 September) over the shocking charge that our Navy had operated a ransom gang that had abduc


The bald truth about fake news, etc.

Friday, 21 September 2018

In its most innocent forms, we may all enjoy a bit of ‘fake news’ and go to bed with a lighter heart and clean conscience. A meme on Facebook urging social media consumers to caution – “You can’t believe everything you read on the internet


Withholding Taxes – What, why, when?

Thursday, 20 September 2018

The tax regime in Sri Lanka historically imposes WHT on both domestic as well as cross border payments. WHT on domestic payments eases revenue collection (e.g.: PAYE) while WHT on cross border payments are adopted by most countries to ensure that the


Withholding Taxes – What, why, when?

Thursday, 20 September 2018

The tax regime in Sri Lanka historically imposes WHT on both domestic as well as cross border payments. WHT on domestic payments eases revenue collection (e.g.: PAYE) while WHT on cross border payments are adopted by most countries to ensure that the


Columnists More